跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
找到 6,746 条关于
“KIT exon 17”
全部
6,746
临床试验
2,746
药物
894
机构
140
资讯
2,966
前天
FDA Accepts Cogent Biosciences' NDA for Bezuclastinib in Advanced Systemic Mastocytosis, PDUFA Set for June 2027
去年
Cogent Bio Presents Bezuclastinib Data Highlighting Long-Term Benefits in Non-Advanced Systemic Mastocytosis
10个月前
Cogent Biosciences Raises $475.3 Million to Advance Bezuclastinib for Systemic Mastocytosis
去年
Cogent Biosciences Secures $400M Debt Financing to Advance Bezuclastinib Through Pivotal Trials
去年
Bezuclastinib Achieves 87% Response Rate in Pivotal Trial for Non-Advanced Systemic Mastocytosis
去年
Extended Imatinib Therapy Shows Promise in High-Risk GIST Patients as Novel Agents Enter Clinical Development
去年
Hoth Therapeutics' HT-KIT Shows Promising Preclinical Results in KIT-Driven Cancers
8个月前
Hoth Therapeutics Secures Chinese Patent for HT-KIT Cancer Program Targeting KIT Signaling Pathways
去年
Sarepta Discontinues Development of Vesleteplirsen for Duchenne Muscular Dystrophy
去年
Capmatinib Demonstrates Sustained Efficacy in MET Exon 14-Mutated NSCLC
第 1 页,共 297 页
上一页
下一页